The FDA approval of the first oral PCSK9 inhibitor for adults with high cholesterol underscores accelerating change in how patients may access PCSK9 biology therapeutics. The move comes as the category expands and competitive pressure grows for less burdensome administration formats, which can affect adherence and real-world uptake.